Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is poised for success in the biopharmaceutical industry due to its diverse pipeline of innovative antibody-based therapies and the recent FDA approvals for its lead product, Vyvgart. The company's management has shown a strategic focus on targeting rare autoimmune diseases with high unmet medical needs, which has resulted in rapid enrollment and strong demand for its treatments. With potential for multi-billion market opportunities and a promising outlook for its key assets, argenx presents a compelling investment opportunity.

Bears say

argenx is a biotech company with a promising product, Vyvgart, which has gained FDA approval for the treatment of rare autoimmune diseases. However, there are risks involved in the attainment of their price target and rating, including clinical, regulatory, or commercial failure. Although the company has a strong focus on innovation and a promising pipeline, it may take time for these products to generate significant revenue, resulting in a negative outlook from a financial analyst's perspective.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,059.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,059.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.